Note: Javascript is disabled or is not supported by your browser. For this reason, some items on this page will be unavailable. For more information about this message, please visit this page: About CDC.gov.

The development of proteomics-based acrylamide biomarkers using surface enhanced laser desorption ionization (SELDI).

Acrylamide (CAS 79-06-1), a widely used industrial chemical, also formed in thermally processed food, is known to produce neurotoxicity, reproductive effects and has been classified as a probable human carcinogen. Bioactivation of acrylamide is reported to occur by CYP2E1 oxidation and GSH conjugation. Protein and DNA adducts have been reported for both Acrylamide and glycidamide (5694-00-8), its oxidative metabolite. In the current study the reaction products of acrylamide and glycidamide with human alpha- and beta-globins or albumin, obtained through in vitro incubation, were studied using Surface Enhanced Laser Desorption Ionization (SELD) with Time of Flight mass spectrometry. The study showed that the reactivity of glycidamide with albumin, alpha-globin and beta-globin was much more than measured after incubation with acrylamide. After 12 hours the glycidamideadduct levels for albumin < alpha-globin < beta-globin, but detectable adduct formation for acrylamide was measured only for albumin. The adduct levels continued to increase during the 72-hour test period. Tryptic digests of the proteins may be utilized for specific proteomic-based biomarkers of exposure to acrylamide or glycidamide.